Express Scripts' new Flex formulary has been touted as an alternative to the rebate-based system, but who really benefits?
Read MoreIn his Sept. 25 article, “Collins’ bills to ban pharmacy ‘gag clauses’ pass House and Senate,” Staff Writer Joe Lawlor reported that the Patient Right to Know Drug Prices Act – sponsored by Maine Republican Sen. Susan Collins – had been approved by both houses of Congress, along with the Know the Lowest Price Act. On Oct. 10, President Trump signed these bills into law.
Read MoreDr. Angus Worthing gives his thoughts on the Patient Right to Know Drug Prices Act and the Know the Lowest Price Act.
Read MoreIn March, Sen. Susan Collins, R-Maine, introduced the Patient Right to Know Drug Prices Act. Backed by a bipartisan group of lawmakers, the bill bans the “gag clauses” that prevent pharmacies from informing consumers whether they could spend less on their medication by paying the full price for an identical product produced by a different manufacturer.
Read More
Sen. Bill Cassidy (R-LA), shared Dr. Levin’s, ATAP President, op-ed on his social media channels highlighting the support ATAP has given to the PBM issue at the federal level.
Read MoreDr. Robert Levin offers insight into pharmacy benefit managers and their lack of transparency.
Read MoreAmericans spend more per capita on prescription drugs than any other high-income country in the world. Many states have wrestled with the rising costs of these medications, particularly in Florida.
Read MoreState efforts to address harmful PBM practices are continuing to gain momentum across the country, with numerous states considering PBM-related legislation this session. Here are some recent state advocacy highlights:
Read MoreATAP is once again pleased to report that Colorado passed a bill (HB 1284) last week aimed at regulating PBMs, the latest in the growing movement sweeping across the nation.
Read More